Skip to main
ANIK

Anika Therapeutics (ANIK) Stock Forecast & Price Target

Anika Therapeutics (ANIK) Analyst Ratings

Based on 1 analyst ratings
Buy
Strong Buy 0%
Buy 100%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Anika Therapeutics Inc. is experiencing significant growth across multiple segments, with management reporting that the Integrity product line is expected to achieve over 100% revenue growth in 2025 compared to 2024. The company has also demonstrated resilience in its international markets, as overseas osteoarthritis pain revenue rose by 13% in the first quarter, complemented by a robust 21% increase in international OA pain revenue from the previous year. Additionally, the regenerative solutions business reported an impressive 41% growth in the quarter, driven primarily by strong demand for the Integrity patch.

Bears say

Anika Therapeutics Inc experienced a decline in revenue, reporting $27.8 million, which reflects a 5.9% decrease compared to the prior year, amidst challenges such as production yield issues. The company also faced a disappointing gross margin of 56%, falling short of the estimated 58%, which adds to concerns about operational efficiency. Additionally, international revenue from osteoarthritis pain management decreased by 10%, indicating persistent difficulties in their product demand and sales performance.

Anika Therapeutics (ANIK) has been analyzed by 1 analysts, with a consensus rating of Buy. 0% of analysts recommend a Strong Buy, 100% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Anika Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Anika Therapeutics (ANIK) Forecast

Analysts have given Anika Therapeutics (ANIK) a Buy based on their latest research and market trends.

According to 1 analysts, Anika Therapeutics (ANIK) has a Buy consensus rating as of Dec 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Anika Therapeutics (ANIK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.